Form 4: Aurinia Pharmaceuticals Director Acquires Stock Options

Aurinia Pharmaceuticals Director Jeffrey Allen Bailey acquired 23,931 stock options with an exercise price of $15.67.

Summary

• Jeffrey Allen Bailey, a Director at Aurinia Pharmaceuticals Inc., acquired 23,931 stock options on June 4, 2026.
• The stock options have an exercise price of $15.67 per share.
• These options are exercisable one year from the date of grant, with an expiration date of June 4, 2036.
• The securities acquired are common shares, with 23,931 shares underlying the options.
• Bailey's ownership of these options is direct.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard insider stock option grant rather than a significant financial event or strategic shift.

Positives

• Director acquisition of stock options can signal confidence in the company's future performance.
• The acquisition of 23,931 options indicates a significant stake being taken by a key insider.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding future financial performance. The details pertain to a stock option grant.

Industry Context

StockSavvy.ai notes that insider stock option grants are common in the biopharmaceutical sector as a means of executive compensation and aligning management interests with shareholder value. The exercise price of $15.67 suggests a valuation point at the time of the grant.

Stakeholder Impact

• Shareholders: The acquisition of options by a director may be viewed positively as it aligns director incentives with potential stock price appreciation.

Next Steps

• The stock options will vest one year from the date of grant.
• The options are exercisable until their expiration date on June 4, 2036.

Key Dates

Keywords

Aurinia Pharmaceuticals, AUPH, Form 4, Stock Options, Director, Beneficial Ownership, Securities Exchange Act